Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study

BACKGROUND: The efficacy and safety of biologic treatments for children and adolescents with moderate to severe psoriasis should be examined over a considerable time period and in different subgroups. OBJECTIVE: We report the efficacy and safety of secukinumab low dose (LD) and high dose (HD) regime...

Descripción completa

Detalles Bibliográficos
Autores principales: Magnolo, Nina, Kingo, Külli, Laquer, Vivian, Browning, John, Reich, Adam, Szepietowski, Jacek C., Keefe, Deborah, Papanastasiou, Philemon, Bao, Weibin, Forrer, Pascal, Patekar, Manmath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205811/
https://www.ncbi.nlm.nih.gov/pubmed/35698000
http://dx.doi.org/10.1007/s40272-022-00507-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205811/
https://www.ncbi.nlm.nih.gov/pubmed/35698000
http://dx.doi.org/10.1007/s40272-022-00507-0

Ejemplares similares